Molecular Partners Net Worth
Molecular Partners Net Worth Breakdown | MOLN |
Molecular Partners Net Worth Analysis
Molecular Partners' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Molecular Partners' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Molecular Partners' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Molecular Partners' net worth analysis. One common approach is to calculate Molecular Partners' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Molecular Partners' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Molecular Partners' net worth. This approach calculates the present value of Molecular Partners' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Molecular Partners' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Molecular Partners' net worth. This involves comparing Molecular Partners' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Molecular Partners' net worth relative to its peers.
Enterprise Value |
|
To determine if Molecular Partners is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Molecular Partners' net worth research are outlined below:
| Molecular Partners had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 4.97 M. Net Loss for the year was (54.04 M) with loss before overhead, payroll, taxes, and interest of (40.4 M). | |
| Molecular Partners AG currently holds about 267.13 M in cash with (59.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from globenewswire.com: Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics |
Molecular Partners uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Molecular Partners AG. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Molecular Partners' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Molecular Partners Target Price Consensus
Molecular target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Molecular Partners' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Strong Buy |
Most Molecular analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Molecular stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Molecular Partners, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMolecular Partners Target Price Projection
Molecular Partners' current and average target prices are 4.23 and 10.73, respectively. The current price of Molecular Partners is the price at which Molecular Partners AG is currently trading. On the other hand, Molecular Partners' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Molecular Partners Market Quote on 17th of December 2025
Target Price
Analyst Consensus On Molecular Partners Target Price
Know Molecular Partners' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Molecular Partners is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Molecular Partners AG backward and forwards among themselves. Molecular Partners' institutional investor refers to the entity that pools money to purchase Molecular Partners' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Suvretta Capital Management, Llc | 2025-06-30 | 2.2 M | Bvf Inc | 2025-06-30 | 1.4 M | Ubs Group Ag | 2025-06-30 | 10.2 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 367 | Bank Of America Corp | 2025-06-30 | 157 | Rhumbline Advisers | 2025-06-30 | 0.0 |
Follow Molecular Partners' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 156.33 M.Market Cap |
|
Project Molecular Partners' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.32) | |
| Return On Capital Employed | (0.41) | (0.44) | |
| Return On Assets | (0.34) | (0.32) | |
| Return On Equity | (0.38) | (0.40) |
When accessing Molecular Partners' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Molecular Partners' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Molecular Partners' profitability and make more informed investment decisions.
Evaluate Molecular Partners' management efficiency
Molecular Partners has return on total asset (ROA) of (0.2701) % which means that it has lost $0.2701 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5142) %, meaning that it created substantial loss on money invested by shareholders. Molecular Partners' management efficiency ratios could be used to measure how well Molecular Partners manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of December 2025, Return On Tangible Assets is likely to grow to -0.32. In addition to that, Return On Capital Employed is likely to drop to -0.44. At this time, Molecular Partners' Debt To Assets are very stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.16 | 5.83 | |
| Tangible Book Value Per Share | 4.16 | 5.83 | |
| Enterprise Value Over EBITDA | (1.49) | (1.41) | |
| Price Book Value Ratio | 0.98 | 0.93 | |
| Enterprise Value Multiple | (1.49) | (1.41) | |
| Price Fair Value | 0.98 | 0.93 | |
| Enterprise Value | 76.7 M | 72.9 M |
The decision-making processes within Molecular Partners are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Molecular Partners time-series forecasting models is one of many Molecular Partners' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Molecular Partners' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Molecular Partners Earnings Estimation Breakdown
The calculation of Molecular Partners' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Molecular Partners is estimated to be -0.23495 with the future projection ranging from a low of -0.3225 to a high of -0.1474. Please be aware that this consensus of annual earnings estimates for Molecular Partners AG is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.32 Lowest | Expected EPS | -0.15 Highest |
Molecular Partners Earnings Projection Consensus
Suppose the current estimates of Molecular Partners' value are higher than the current market price of the Molecular Partners stock. In this case, investors may conclude that Molecular Partners is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Molecular Partners' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 4 | 49.27% | 0.0 | -0.23495 | -2.03 |
Molecular Partners Earnings per Share Projection vs Actual
Actual Earning per Share of Molecular Partners refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Molecular Partners AG predict the company's earnings will be in the future. The higher the earnings per share of Molecular Partners, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Molecular Partners Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Molecular Partners, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Molecular Partners should always be considered in relation to other companies to make a more educated investment decision.Molecular Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Molecular Partners' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-10-30 | 2025-09-30 | -0.4795 | -0.33 | 0.1495 | 31 | ||
2025-08-25 | 2025-06-30 | -0.4995 | -0.6841 | -0.1846 | 36 | ||
2025-04-17 | 2025-03-31 | -0.37 | -0.45 | -0.08 | 21 | ||
2025-03-06 | 2024-12-31 | -0.39 | -0.3 | 0.09 | 23 | ||
2024-10-31 | 2024-09-30 | -0.6288 | -0.5629 | 0.0659 | 10 | ||
2024-08-27 | 2024-06-30 | -1.26 | -0.46 | 0.8 | 63 | ||
2024-05-16 | 2024-03-31 | -1 | -0.6 | 0.4 | 40 | ||
2024-03-14 | 2023-12-31 | -0.97 | -0.6 | 0.37 | 38 | ||
2023-10-26 | 2023-09-30 | 0 | -0.3943 | -0.3943 | 0 | ||
2023-08-28 | 2023-06-30 | -0.87 | -0.5417 | 0.3283 | 37 | ||
2023-05-11 | 2023-03-31 | 0 | -0.4906 | -0.4906 | 0 | ||
2023-03-09 | 2022-12-31 | -0.9 | -0.54 | 0.36 | 40 | ||
2022-10-27 | 2022-09-30 | -0.6559 | -0.4238 | 0.2321 | 35 | ||
2022-08-29 | 2022-06-30 | -0.6559 | 4.59 | 5.2459 | 799 | ||
2022-05-12 | 2022-03-31 | -0.6559 | 4.62 | 5.2759 | 804 | ||
2022-03-15 | 2021-12-31 | -1.04 | -0.56 | 0.48 | 46 | ||
2021-10-28 | 2021-09-30 | -0.6013 | -0.6013 | 0.0 | 0 | ||
2021-08-26 | 2021-06-30 | -0.6231 | -0.6231 | 0.0 | 0 | ||
2021-06-16 | 2021-03-31 | -0.7915 | -0.6177 | 0.1738 | 21 | ||
2021-02-26 | 2020-12-31 | 0 | -0.6009 | -0.6009 | 0 | ||
2020-12-31 | 2020-09-30 | 0 | -0.7589 | -0.7589 | 0 | ||
2020-09-30 | 2020-06-30 | 0 | -0.6524 | -0.6524 | 0 | ||
2020-06-30 | 2020-03-31 | 0 | -0.5528 | -0.5528 | 0 | ||
2020-03-31 | 2019-12-31 | 0 | -0.6406 | -0.6406 | 0 | ||
2019-12-31 | 2019-09-30 | 0 | -0.5658 | -0.5658 | 0 | ||
2019-09-30 | 2019-06-30 | 0 | -0.5485 | -0.5485 | 0 | ||
2019-06-30 | 2019-03-31 | 0 | -0.3061 | -0.3061 | 0 | ||
2019-03-31 | 2018-12-31 | 0 | -0.3001 | -0.3001 | 0 | ||
2018-12-31 | 2018-09-30 | 0 | -0.6068 | -0.6068 | 0 | ||
2018-09-30 | 2018-06-30 | 0 | -0.6077 | -0.6077 | 0 | ||
2018-06-30 | 2018-03-31 | 0 | -0.2832 | -0.2832 | 0 | ||
2018-03-31 | 2017-12-31 | 0 | -0.2909 | -0.2909 | 0 | ||
2017-12-31 | 2017-09-30 | 0 | -0.1482 | -0.1482 | 0 | ||
2017-09-30 | 2017-06-30 | 0 | -0.1491 | -0.1491 | 0 | ||
2017-06-30 | 2017-03-31 | 0 | -0.5851 | -0.5851 | 0 | ||
2017-03-31 | 2016-12-31 | 0 | -0.3695 | -0.3695 | 0 | ||
2016-12-31 | 2016-09-30 | 0 | -0.1792 | -0.1792 | 0 | ||
2016-09-30 | 2016-06-30 | 0 | -0.2574 | -0.2574 | 0 | ||
2016-06-30 | 2016-03-31 | 0 | -0.2796 | -0.2796 | 0 | ||
2016-03-31 | 2015-12-31 | 0 | -0.2191 | -0.2191 | 0 | ||
2015-12-31 | 2015-09-30 | 0 | 0.0595 | 0.0595 | 0 | ||
2015-09-30 | 2015-06-30 | 0 | 0.256 | 0.256 | 0 | ||
2015-06-30 | 2015-03-31 | 0 | -0.2416 | -0.2416 | 0 | ||
2015-03-31 | 2014-12-31 | 0 | -0.134 | -0.134 | 0 | ||
2014-12-31 | 2014-09-30 | 0 | -0.2799 | -0.2799 | 0 | ||
2014-09-30 | 2014-06-30 | 0 | 0.069 | 0.069 | 0 | ||
2014-06-30 | 2014-03-31 | 0 | 0.0513 | 0.0513 | 0 | ||
2014-03-31 | 2013-12-31 | 0 | 0.0515 | 0.0515 | 0 |
Molecular Partners Corporate Management
| Robert Hendriks | Senior Finance | Profile | |
| Alexander Zurcher | COO Board | Profile | |
| Martin Steegmaier | Chief Officer | Profile | |
| Michael Pitzner | Compliance Counsel | Profile | |
| MD MBA | Interim Officer | Profile | |
| Daniel Steiner | Senior Technology | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.